Verona Pharma to Present at Jefferies London Healthcare Conference

Company Overview - Verona Pharma plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs [3] - The company's first commercial product, OhtuvayreTM (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [3] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [3] Upcoming Event - Senior management will present a company overview at the Jefferies London Healthcare Conference on November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT [1] - A webcast of the event will be available on the company's website [1]